Antiviral Agents
6
0
1
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
33.3%
2 terminated out of 6 trials
50.0%
-36.5% vs benchmark
17%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Antiviral Long Acting Drugs Landing in People Living With HIV
Screening of Volunteers for Clinical Trials of Investigational or Licensed Vaccines or Antiviral Products
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.